These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 29385867)
1. Combination Therapy with Tenofovir Disoproxil Fumarate/Emtricitabine/Elvitegravir/Cobicistat Plus Darunavir Once Daily in Antiretroviral-Naive and Treatment-Experienced Patients: A Retrospective Review. Naccarato MJ; Yoong DM; Fong IW; Gough KA; Ostrowski MA; Tan DHS J Int Assoc Provid AIDS Care; 2018; 17():2325957417752260. PubMed ID: 29385867 [TBL] [Abstract][Full Text] [Related]
2. Co-administration of elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine and atazanavir in treatment-experienced HIV patients. Biagi M; Badowski ME; Chiampas T; Young J; Patel M; Vaughn P Int J STD AIDS; 2017 Jul; 28(8):766-772. PubMed ID: 27587601 [TBL] [Abstract][Full Text] [Related]
3. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. Cohen C; Elion R; Ruane P; Shamblaw D; DeJesus E; Rashbaum B; Chuck SL; Yale K; Liu HC; Warren DR; Ramanathan S; Kearney BP AIDS; 2011 Mar; 25(6):F7-12. PubMed ID: 21412057 [TBL] [Abstract][Full Text] [Related]
4. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. DeJesus E; Rockstroh JK; Henry K; Molina JM; Gathe J; Ramanathan S; Wei X; Yale K; Szwarcberg J; White K; Cheng AK; Kearney BP; Lancet; 2012 Jun; 379(9835):2429-2438. PubMed ID: 22748590 [TBL] [Abstract][Full Text] [Related]
5. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Sax PE; DeJesus E; Mills A; Zolopa A; Cohen C; Wohl D; Gallant JE; Liu HC; Zhong L; Yale K; White K; Kearney BP; Szwarcberg J; Quirk E; Cheng AK; Lancet; 2012 Jun; 379(9835):2439-2448. PubMed ID: 22748591 [TBL] [Abstract][Full Text] [Related]
6. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data. Mills A; Crofoot G; Ortiz R; Rashbaum B; Towner W; Ward D; Brinson C; Kulkarni R; Garner W; Ebrahimi R; Cao H; Cheng A; Szwarcberg J HIV Clin Trials; 2014; 15(2):51-6. PubMed ID: 24710918 [TBL] [Abstract][Full Text] [Related]
7. Virological failure in two patients with HIV-1 RNA viral loads >1,000,000 copies/ml initiated on elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate. Adams JL; Byrne D; Pepe R; Gray A; Baxter JD Antivir Ther; 2016; 21(2):175-80. PubMed ID: 26308882 [TBL] [Abstract][Full Text] [Related]
8. HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study. Harris M; Ganase B; Watson B; Harrigan PR; Montaner JSG; Hull MW AIDS Res Ther; 2017 Nov; 14(1):59. PubMed ID: 29096670 [TBL] [Abstract][Full Text] [Related]
9. Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): a review of its use in the management of HIV-1 infection in adults. Perry CM Drugs; 2014 Jan; 74(1):75-97. PubMed ID: 24338165 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects. Ramanathan S; Custodio JM; Wei X; Wang H; Fordyce M; Dave A; Ling KH; Szwarcberg J; Kearney BP J Acquir Immune Defic Syndr; 2016 Jul; 72(3):281-8. PubMed ID: 26885802 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study. Suárez-García I; Moreno C; Ruiz-Algueró M; Pérez-Elías MJ; Navarro M; Díez Martínez M; Viciana P; Pérez-Martínez L; Górgolas M; Amador C; de Zárraga MA; Jarrín I; AIDS Res Ther; 2020 Jul; 17(1):45. PubMed ID: 32690099 [TBL] [Abstract][Full Text] [Related]
12. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine. Cid-Silva P; Fernández-Bargiela N; Margusino-Framiñán L; Balboa-Barreiro V; Mena-De-Cea Á; López-Calvo S; Vázquez-Rodríguez P; Martín-Herranz I; Míguez-Rey E; Poveda E; Castro-Iglesias Á Basic Clin Pharmacol Toxicol; 2019 Apr; 124(4):479-490. PubMed ID: 30388308 [TBL] [Abstract][Full Text] [Related]
13. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1. Eron JJ; Orkin C; Cunningham D; Pulido F; Post FA; De Wit S; Lathouwers E; Hufkens V; Jezorwski J; Petrovic R; Brown K; Van Landuyt E; Opsomer M; Antiviral Res; 2019 Oct; 170():104543. PubMed ID: 31279073 [TBL] [Abstract][Full Text] [Related]
14. Optimal HIV Postexposure Prophylaxis Regimen Completion With Single Tablet Daily Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine Compared With More Frequent Dosing Regimens. Mayer KH; Jones D; Oldenburg C; Jain S; Gelman M; Zaslow S; Grasso C; Mimiaga MJ J Acquir Immune Defic Syndr; 2017 Aug; 75(5):535-539. PubMed ID: 28696345 [TBL] [Abstract][Full Text] [Related]
15. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients. White KL; Kulkarni R; McColl DJ; Rhee MS; Szwarcberg J; Cheng AK; Miller MD Antivir Ther; 2015; 20(3):317-27. PubMed ID: 25321623 [TBL] [Abstract][Full Text] [Related]
16. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients. Kulkarni R; Abram ME; McColl DJ; Barnes T; Fordyce MW; Szwarcberg J; Cheng AK; Miller MD; White KL HIV Clin Trials; 2014; 15(5):218-30. PubMed ID: 25350960 [TBL] [Abstract][Full Text] [Related]
17. Baseline antiretroviral resistance mutations and treatment-emergent resistance in HIV-1 RNA-suppressed patients switching to EVG/COBI/FTC/TDF or continuing on their PI-, NNRTI-, or RAL-based regimen. Andreatta K; Kulkarni R; Abram ME; Nguyen T; Cao H; Miller MD; White KL J Acquir Immune Defic Syndr; 2015 Apr; 68(5):519-26. PubMed ID: 25559592 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and bioequivalence evaluation of single-tablet and separate-tablet regimens for once-daily cobicistat-boosted elvitegravir in healthy Japanese male subjects: A randomized, two-way crossover study. Shiomi M; Matsuki S; Ikeda A; Ishikawa T; Nishino N; Kimura M; Kumagai Y; Irie S Clin Pharmacol Drug Dev; 2015; 4(3):218-25. PubMed ID: 27140802 [TBL] [Abstract][Full Text] [Related]
19. Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF. Gathe J; Arribas JR; Van Lunzen J; Garner W; Speck RM; Bender R; Shreay S; Nguyen T Patient; 2015 Oct; 8(5):445-54. PubMed ID: 26286337 [TBL] [Abstract][Full Text] [Related]
20. Clinical Outcomes Associated With Once-Daily Ritonavir-Boosted Darunavir Plus Tenofovir/Emtricitabine in HIV-Infected Patients Harboring at Minimum a M184V/I Resistance Mutation. Sahloff EG; Duggan JM Ann Pharmacother; 2019 Jan; 53(1):50-55. PubMed ID: 30047788 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]